Latest news

PCI Biotech to present poster at the Second International Cancer Immunotherapy Conference

Posted on Sep 23, 2016

Oslo, September 23, 2016 – PCI Biotech will present a poster at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 2016. This year’s event is called “Translating Science into Survival” and is held at the Sheraton Times Square Hotel and the New York Hilton Midtown in New York City, September 25-28, 2016. The company will be represented by […]

PCI Biotech to present phase I results at Nordic Life Science Days 2016

Posted on Sep 13, 2016

Oslo, September 13, 2016 – PCI Biotech will present at Nordic Life Science Days 2016 on Wednesday, September 14, 2016, 17:00 local time at Stockholm Waterfront Congress Center (room 24/25 on level 2), Stockholm, Sweden. The presentation is attached and includes results from the phase I bile duct cancer study. The presentation will be held […]

Independent evaluation confirms early promising signs of efficacy in the phase I/II bile duct cancer study

Posted on Sep 6, 2016

Oslo, 6 September 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company reported today an update on the phase I/II study in inoperable bile duct cancer patients. The phase I part of the study has been completed with good tolerability and promising early signs of efficacy. The independent evaluation of the radiology data […]